4.7 Article

Systematic Identification of Oncogenic EGFR Interaction Partners

期刊

JOURNAL OF MOLECULAR BIOLOGY
卷 429, 期 2, 页码 280-294

出版社

ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.jmb.2016.12.006

关键词

two-hybrid screening; protein-protein interaction; EGFR; non-small cell lung cancer; oncogenic signaling

资金

  1. UK Medical Research Council
  2. BBSRC [BB/JO/5881/1]
  3. Deutsche Forschungsgemeinschaft [Ke904/2-1]
  4. Ontario Genomics Institute
  5. Canadian Cystic Fibrosis Foundation
  6. Canadian Cancer Society
  7. Pancreatic Cancer Canada
  8. University Health Network
  9. Ontario Research Fund [GL2-01-030]
  10. Canada Research Chair Programs
  11. EC-Marie Curie International Incoming Fellowship [FP7-PEOPLE-2013-IIF]
  12. Medical Research Council [MC_EX_G0800785, MC_U12266B, MC_CF12266] Funding Source: researchfish
  13. MRC [MC_EX_G0800785] Funding Source: UKRI

向作者/读者索取更多资源

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (TK) that once activated upon ligand binding leads to receptor dimerization, recruitment of protein complexes, and activation of multiple signaling cascades. The EGFR is frequently overexpressed or mutated in various cancers leading to aberrant signaling and tumor growth. Hence, identification of interaction partners that bind to mutated EGFR can help identify novel targets for drug discovery. Here, we used a systematic approach to identify novel proteins that are involved in cancerous EGFR signaling. Using a combination of high-content imaging and a mammalian membrane two-hybrid protein protein interaction method, we identified eight novel interaction partners of EGFR, of which half strongly interacted with oncogenic, hyperactive EGFR variants. One of these, transforming acidic coiled-coil proteins (TACC) 3, stabilizes EGFR on the cell surface, which results in an increase in downstream signaling via the mitogen-activated protein kinase and AKT pathway. Depletion of TACC3 from cells using small hairpin RNA (shRNA) knockdown or small-molecule targeting reduced mitogenic signaling in non-small cell lung cancer cell lines, suggesting that targeting TACC3 has potential as a new therapeutic approach for non-small cell lung cancer. (C) 2016 The Authors. Published by Elsevier Ltd.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据